BIIB-104
BIIB-104, also known as PF-04958242 is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which is under development by Pfizer for the treatment of cognitive symptoms in schizophrenia. It was also under development for the treatment of age-related sensorineural hearing loss, but development for this indication was terminated due to insufficient effectiveness. As of July 2018, BIIB-104 is in phase II clinical trials for cognitive symptoms in schizophrenia.
primaryTopic
BIIB-104
BIIB-104, also known as PF-04958242 is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which is under development by Pfizer for the treatment of cognitive symptoms in schizophrenia. It was also under development for the treatment of age-related sensorineural hearing loss, but development for this indication was terminated due to insufficient effectiveness. As of July 2018, BIIB-104 is in phase II clinical trials for cognitive symptoms in schizophrenia.
has abstract
BIIB-104, also known as PF-049 ...... tracellular levels of glycine.
@en
CAS number
1258963-59-5
FDA UNII code
9G1A824CC2
PubChem
Wikipage page ID
55,085,415
page length (characters) of wiki page
Wikipage revision ID
995,948,606
Link from a Wikipage to another Wikipage
CAS number
ChemSpiderID
32,698,813
IUPAC name
N-[-4-[4-phenoxy]oxolan-3-yl]propane-2-sulfonamide
@en
PubChem
49,853,967
SMILES
CCSN[C@H]1COC[C@H]1OC2=CC=CC3=CC=CC#N
@en
StdInChIKey
TTYKUKSFWHEBLI-DLBZAZTESA-N
@en
synonyms
PF-04958242
@en
wikiPageUsesTemplate
subject
comment
BIIB-104, also known as PF-049 ...... ive symptoms in schizophrenia.
@en
label
BIIB-104
@en